07:00 , Apr 13, 2009 |  BC Week In Review  |  Clinical News

AVN-101: Phase I started

Avineuro began an open-label, placebo-controlled, Russian Phase I trial to evaluate oral AVN-101 in 16 healthy volunteers. Avineuro Pharmaceuticals Inc. , San Diego, Calif.   Product: AVN-101   Business: Neurology   Molecular target: Serotonin (5-HT)...